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Abstract
INTRODUCTION In light of expanding use of pilocarpine for numerous systemic disorders over the past decades, it 
is important to understand its effects on visual and oral function.
OBJECTIVE  To study the adverse effects of topical pilocarpine on visual and oral function in healthy volunteers via 
interprofessional collaboration. 
METHODS Thirty-six subjects, 21 years and older, were enrolled for the study. The study was designed to have each 
subject undergo tests for oral and visual function before and 20 minutes after a topical dose (2% ophthalmic solution), 
so the subjects served as their own controls.
RESULTS The sample included 24 females and 11 males with a mean of 22 years. The pupil diameter was significantly 
reduced post treatment with pilocarpine. The effect was larger in dim light than in bright light. Distance and near vi-
sual acuity were significantly reduced by pilocarpine treatment. Distance visual acuity under low contrast illumination 
and automated perimetry were significantly reduced with pilocarpine. Remarkably, salivary volume was significantly 
increased.
CONCLUSION In young normal subjects, pilocarpine adversely affects the visual acuity, contrast sensitivity, visual 
field and thus the overall visual function, but it positively increases salivary volume.
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© 2012 Hua et al. This open access article is distributed under a Creative Commons Attribution License, which allows unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
Pilocarpine is a natural alkaloid derived from the leaves 
of a plant, pilocarpus jaborandi, indigenous to South 
America (Vivino et al., 1999). Pilocarpine hydrochlo-
ride is known as a direct-acting cholinergic agonist that 
activates muscarinic receptors [M1-M5] nonspecifical-
ly resulting in a broad spectrum of pharmacological ef-
fects. It stimulates exocrine secretions from sweat, sali-
vary, and lacrimal glands (Brown & Taylor, 2006). It is 
indicated for the treatment of inadequate salivary flow 
secondary to radiation therapy for cancers of the head 
and neck. It is also commonly used in patients with Sjo-
gren’s syndrome, which is a chronic autoimmune dis-
ease that gradually damages the moisture-producing 
glands, causing significant dryness in the mouth and 
eyes (Bruce, 2003). 
In eye care, pilocarpine has been one of the earliest 
drugs used in the treatment of glaucoma (Grierson 
et al., 1978). Although it is no longer the first line of 
drug prescribed for treatment of glaucoma, pilocarpine 
is still being used widely to treat acute angle closure 
and to prepare the iris for laser peripheral iridotomy. 
Moreover, it is still a glaucoma drug of choice for many 
patients in third world countries because of its afford-
ability (Wu et al., 2011). 
Muscarinic receptors are found on the secretory exo-
crine gland, on smooth and cardiac muscles, and dis-
tributed throughout the central nervous system includ-
ing the eyes (Eglen, 2006). Pilocarpine acts unselectively 
on multiple subtypes of muscarinic receptors therefore 
it can cause various parasymthomimetic effects. Stim-
ulation of peripheral muscarinic receptors produces 
salivation, lacrimation, sweating, rhinorrhea, bron-
chospasm, urinary frequency, diarrhea, bradycardia, 
and miosis. It is generally known that miosis induced 
by topical pilocarpine can adversely affects visual field, 
and ciliary spasm can cause reduction in accommoda-
tion and visual acuity (McCluskey et al., 1986; Gilmar-
tin, Amer, & Ignleby, 1995). Although there have been 
a number of studies over the past few decades on the ef-
fects of topical pilocarpine on high-contrast visual acu-
ity and visual field with respect to glaucoma treatment, 
little has been done to investigate the potential effect of 
topical pilocarpine on low-contrast visual acuity which 
is encountered in many daily environmental settings. 
Furthermore, the effects of topical pilocarpine on oral 
function are not well-documented. 
In light of expanding use of pilocarpine for numerous 
systemic disorders over the past decades, it is impor-
tant to understand its adverse effects on visual and oral 
function. Therefore, we designed an interprofessional 
study to look at the effects of topical pilocarpine on vi-
sual function including low-contrast sensitivity; and its 
effects on oral function in healthy volunteers. 
             Implications for Interprofessional Practice
•	 Topical pilocarpine can induce headache as a side effect in young patients.  
•	 Topical pilocarpine can significantly reduce visual acuity, especially in natural (low contrast) environ-
ment.
•	 Oral pilocarpine causes miosis and can also reduce visual acuity. 
•	 Clinicians who prescribe pilocarpine or other miotic drugs need to pay closer attention to the ocular 
side effects of this class of drug because they can signicantly affect the daily tasks that require clear 
vision.
•	 Over the years, there has been an expanding use of miotics in medicine, so miosis-induced visual 
impairment affects an increasing number of patients, especially the elderly.
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Materials and methods
Thirty-five subjects, between 21 and 38 years of age, 
were enrolled for the study. All subjects were required to 
fill out informed consent forms, medical intake forms, 
and questionnaires related to ocular and dental health. 
The study was designed to have each subject undergo 
tests for oral and visual function before and 20 minutes 
after a topical dose (2 percent ophthalmic solution), so 
the subjects served as their own controls. Pilocarpine 
hydrochloride ophthalmic solution 2 percent (Bausch 
+ Lomb, FL, USA) was used for the study. The study 
was reviewed and approved by Pacific University Insti-
tutional Review Board before initiation.
The study location was the Pacific University Eye and 
Dental Clinics. Investigation oral hydration was per-
formed using Saliva-Check BUFFER kit (GC Corpora-
tion, Tokyo, Japan). Prior to the dental visit, subjects 
were instructed not to smoke, consume food or drink, 
brush teeth, or use a mouth wash for at least one hour 
before the scheduled appointment time. The lower lip 
was blotted dry with a small piece of gauze and the ex-
aminer observed the mouth skin under good illumina-
tion. Level of hydration was inspected by measuring 
how long it took for saliva to form inside the lower 
lip. The volume of saliva was collected and measured 
by having subjects chew on a piece of wax to stimulate 
salivary flow and spat intermittently into the cup over 
a period of five minutes. The thickness of the saliva was 
examined for salivary consistency by observation. The 
pH of the saliva was tested with a pH test strip. Buffer-
ing capacity of the saliva was done via a simple chemi-
cal test supplied with the kit.
Visual function was assessed by visual acuity (VA), con-
trast sensitivity and visual field. The size of pupil was 
also measured under bright and dim light. Distance VA 
was measured at 20 feet using LogMAR optotypes via 
Pro Video System (Innova System Inc, IL, USA). Near 
VA was taken at 16 inches using pocket-sized near vi-
sion card with Sloan letters (Good-Lite, IL, USA). Con-
trast sensitivity testing was measured using 5 percent 
chart in LogMAR sizes at 10 feet (Good-Lite, IL, USA). 
Visual field was tested via N-30-5 FDT screening on 
Humphrey Matrix (Carl Zeiss Meditec Inc, CA, USA). 
Pupil sizes were measured in bright and dim illumi-
nation using pupil gauge on pocket-sized near vision 
card. In addition, pictures of pupil size were taken using 
Handycam HDR-CX550V with infrared feature (Sony 
Corporation, Tokyo, Japan).  
Statistical analysis
Descriptive statistics provided the basic findings. OD 
and OS measures were averaged to provide a single val-
ue. Before and after treatment values were compared 
with a paired t-test. 
Results
Sample and Survey 
The sample included 24 females and 11 males with ages 
ranging from 22 to 38 with a mean of 22 years. Ten (10) 
reported no dry eye complaints, nine rarely had dry 
eye, 15 reported sometimes, and one always. Seventeen 
had no night time vision complaints and nine rarely 
had complaints, while nine sometimes had problems, 
three usually, and one always. Four people complained 
of dry mouth. Table 1 (following page) summarizes the 
numeric variables collected.
Visual Function 
Table 2 (following page) summarizes the change scores 
for different visual tests. The pupil diameter was sig-
nificantly reduced post treatment with pilocarpine. The 
effect was larger in dim light than in bright light. Rep-
resentative photographs of pupils before and after pilo-
carpine treatment are shown in Figures 1a and 1b (page 
5). Both distance and near visual acuity (VA) were sig-
nificantly reduced by pilocarpine treatment with larger 
effects on distance VA. Distance visual acuity under 
low-contrast illumination was significantly reduced 
with pilocarpine. Automated perimetry was also sig-
nificantly affected by pilocarpine. Representative print-
outs of VF results are presented in Figure 2 (page 6). 
Salivary Function
Salivary consistency, buffering capacity, and pH of the 
saliva were not significantly affected by topical pilo-
carpine, but the salivary volume was significantly in-
creased (see Table 2) .
Discussion
Pilocarpine, a direct acting cholinergic agonist, has 
been proven to be effective in the treatment of radia-
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N = 35 Minimum Maximum Mean Std. Deviation
Saliva Volume 
Before
4.0 16.0 8.314 3.2315
Saliva Volume After 5.0 17.0 9.757 2.9812
Pupil Size Dim 
Before
4.0 8.0 5.586 1.0743
Pupil Size Light 
Before
2.0 7.5 3.786 1.1394
Pupil Size After 1.5 4.0 2.814 .6869
VA Distance Before 1.5 4.5 2.614 .7484
VA Near Before 1.50 4.25 2.7143 .65626
VA Distance After 11 31 17.14 3.719
VA Near After 10 25 16.09 2.934
Contrast Sensitivity 
Before
11.5 25.5 16.614 2.8622
Contrast Sensitivity 
After
16 30 20.34 2.169
Stinging Rate 16 25 20.06 1.371
Visual Field Before 16.0 25.0 20.200 1.5913
Visual Field After 13 200 52.91 53.559
Headache Rate 15 399 66.00 78.714
Eyestrain Rate 16.0 299.0 59.457 64.3590
After – Before Mean Difference Std. Deviation Paired t (df=35) p
Saliva Volume 1.4429 1.9470 4.384 .000
Pupil Size Dim -2.7714 1.1653 -14.070 .000
Pupil Size Light -1.1714 1.1628 -5.960 .000
VA Distance 36.3000 53.8179 3.990 .000
VA Near 12.8000 25.1160 3.015 .005
Contrast Sensitivity 54.2429 50.0747 6.409 .000
Visual Fields 3.029 5.199 3.446 .002
Note: The variables in Table 2 were examined for association with dry eye, night vision complaints, and dry mouth (non-parametric 
median tests). There were no significant relationships.
Table 1
Numeric variables collected
Table 2
Change scores (post-application – pre-application) for numeric variables (left and right eyes averaged)
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Figure 1a
Photograph of pupil diameter of a representative subject  in dim light before treatment
Figure 1b
Photograph of pupil diameter of the subject in dim light after treatment
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Figure 2a
N-30-5 FDT Screening of another representative subject  before pilocarpine treatment
Figure 2b
N-30-5 FDT Screening of the subject after pilocarpine treatment
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tion-induced xerostomia (Greenspan & Daniels, 1995). 
It was also found to increase salivary flow in patients 
with Sjogren’s syndrome (Vivino et al., 1999; Fox et al., 
1991). Therefore, pilocarpine (Salagen) tablets are com-
monly prescribed both for the treatment of dry mouth 
as a result of radiation therapy for cancers of the head 
and neck; and for dry mouth and dry eyes secondary 
to Sjogren’s syndrome. Moreover, a number of studies 
over the years had shown that pilocarpine was also ef-
fective in relieving inadequate salivary flow caused by 
opioid psychoactive medications, with antimuscarinic 
and anticholinergic properties, leading to the increas-
ing usage of pilocarpine (Sebastiano, 1998; Gotrick et 
al., 2004; Masters, 2005). 
While oral pilocarpine has been prescribed more fre-
quently over the last decade, the use of topical pilo-
carpine has declined and replaced by newer and more 
effective glaucoma medications. Nevertheless, topical 
pilocarpine is still being used widely in third world 
countries for treatment of glaucoma because of its af-
fordability. Furthermore, it is still being utilized to 
relieve intraocular spike in acute angle closure and 
to prepare pupil for laser peripheral iridotomy. Alto-
gether, topical pilocarpine still remains an important 
drug in glaucoma management hence it is important 
to investigate its effects on visual function. This study 
aims to study the effects of topical pilocarpine on visual 
function and also examine its potential effects on oral 
function in healthy volunteers. In addition, the study 
may provide useful data for future study on the effects 
of oral pilocarpine.
Topical pilocarpine has been known for decades to 
cause miosis via stimulation of muscarinic receptors 
present on constrictor muscles of the iris. Miosis is a 
physiological response regulating the amount of light 
reaching the retina for optimal vision. Pharmacological 
miosis, however, is unnatural because the pupil is fixed 
and unresponsive to light and excessive miosis can in-
duce diffraction which interferes with vision.
The data from the study confirmed that a single instil-
lation of pilocarpine significantly reduced the pupil di-
ameters in normal subjects. The effect was larger in dim 
than in bright illumination. Both distance and near vi-
sual acuity were significantly reduced by pilocarpine 
treatment with larger effects on distance VA. Contrast 
sensitivity (CS) testing further assesses visual function 
beyond visual acuity because VA test only measures 
at one high-contrast level, daily activities, however, 
consist of different low contrast environments. Some 
patients can have normal visual acuity, but have dif-
ficulty in doing daily tasks because of reduced CS at 
lower spatial frequencies. Therefore, it is important to 
test VA with low contrast optotype to better represent 
natural environment. The distance visual acuity under 
low-contrast illumination was decreased most signifi-
cantly by topical pilocarpine. This finding is similar to 
what was found in previous study by Edgar et al. (Ed-
gar et al., 1999). On the contrary, another study con-
ducted by Sloane et al. on the effect of senile miosis 
(n=11, M age=73) on contrast sensitivity comparing to 
young adults (n=13, M age=24) found that older adults’ 
miotic pupils actually improved contrast sensitivity 
(Sloane, Owsley, Alvarez, 1988).The difference found 
in our study may be accounted for by the fact that pupil 
sizes induced by pilocarpine was significantly smaller 
as compared to senile miosis and thus diffraction could 
be an important factor affecting the vision in the young 
cohorts.
Automated perimetry is an additional method to assess 
a person’s visual function. It permits a thorough assess-
ment of both the central and peripheral visual field. 
Topical pilocarpine significantly reduced the field of vi-
sion affecting more of the peripheral field than central 
field. The effects of pilocarpine on automated perim-
etry was consistent with previous studies (McCluskey 
et al, 1986; Webster et al, 1993). 
Cumulatively, the significant effects of topical pilocar-
pine on multiple visual tests and overall visual function 
could be attributed by the miotic effects of pilocarpine. 
Excessive miosis can decrease vision in two ways: de-
creased retinal illumination and the presence of dif-
fraction (Campbell & Green, 1965). Optimal visual 
resolution is achieved when the pupil sizes are neither 
too large nor too small. Large pupils are more prone to 
optical aberrations, whereas small pupils are subjected 
to diffractions (Campbell & Gubisch, 1966). The pupil 
size for best axial resolution in the human was found 
to be about 4.30mm ± 1.90mm in a recent study (Don-
nelly & Roorda, 2003). According to Weber’s law, the 
differential light threshold remains unchanged when 
the pupil size is altered, however the law only holds 
when the pupils are ranging approximately 3.0 mm to 
7.0 mm under mesopic illumination levels (Edgar et al., 
1999; Herse, 1992). In our study, a substantial number 
of subjects had pupil diameters below 3.0 mm, at which 
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significant reduction in retinal illumination and dif-
fraction could occur and break Weber’s law as a pos-
sible explanation for significant worsening of visual 
function.
In addition to the effects of pilocarpine on visual func-
tion, other side effects were noted by the majority of 
subjects including severe stinging upon instillation and 
supraorbital headache. Since our subjects were rela-
tively young, ciliary spasm and over accommodation 
caused by cholinergic stimulation can account for the 
headache symptom. On the other hand, a number of 
subjects appreciated a relief of dry eyes with pilocar-
pine. However, this benefit was outweighed by the dis-
comfort of headache and blurry vision. Thus, the sub-
jects would not choose to use it to treat dry eye (based 
on survey questionnaire). Moreover, miotic agents have 
been found occasionally to cause retinal detachment 
and macular hole (Walker, 2007). 
Salivary function
Saliva lubricates, cleans, and protects the oral tissues 
from infectious microorganisms. It also facilitates 
chewing, digesting, tasting, and swallowing of food (At-
kinson, 2005). Xerostomia is a symptom of dryness in 
the mouth associated with salivary hypofunction due to 
various etiologies including autoimmune disease (Sjo-
gren’s), systemic disease (diabetes mellitus), anticho-
linergic effects of many drugs and aging (Narhi, 1999). 
Chronic xerostomia can significantly affect the quality 
of life because of the increased risk of dental cavities, 
oral ulcers and mucosal infection (Perno Goldie, 2007). 
The drug of choice for stimulating salivary flow in the 
treatment of xerostomia is either pilocarpine or cevime-
line (Fox & Michelson, 2000; Porter, Scully & Hegarty, 
2004). Pilocarpine (Salagen®) is available in both tab-
let formulation (5 mg) and 1 and 2 percent solutions 
(Bruce, 2003). Although oral pilocarpine has been 
known for decades to effectively increase the salivary 
volume, the effects of topical pilocarpine (2 percent) 
on salivary volume has not been measured. While we 
studied the effects of topical pilocarpine on visual func-
tion, we also wanted to know whether it might affect 
oral function. Remarkably, the data indicated that there 
was a significant effect of topical pilocarpine on salivary 
volume. The significant effects of topical pilocarpine on 
oral function suggested that there was residual pilocar-
pine reaching the salivary glands via the nasal lacrimal 
ducts from the eyes. Further study is needed to exam-
ine whether the increased in salivary volume by topical 
pilocarpine is clinically beneficial.
Chronic use of pilocarpine (12 weeks or more) has been 
shown to cause diaphoresis, increased urinary frequen-
cy and facial flushing (Nieuw Amerongen & Veerman, 
2003). Serious pilocarpine toxicity is rare, but has been 
reported in a case of idiosyncratic reaction to the drug. 
The patient’s heart rate was slowed to 38 beats per min-
utes and the blood pressure was decreased to 102/42 
mm Hg. Intravenous atropine (0.5 mg) over two min-
utes was used successfully as an antidote (Hendrickson, 
Marocco & Greenberg, 2003). Therefore, it is important 
to educate patients on potential symptoms of pilocar-
pine toxicity.
This study provides further support to previous stud-
ies on the effects of topical pilocarpine on visual func-
tion including contrast sensitivity. Interestingly, topical 
pilocarpine can significantly stimulate salivary volume 
and may relieve dry mouth symptom in patients who 
happens to take the drop topically for glaucoma. One 
difference in this study is that it focused more on vi-
sual function in general, whereas most previous stud-
ies concentrated on the effects of topical pilocarpine on 
visual field with respect to glaucoma treatments. The 
study also looked at the possible effects of topical pilo-
carpine on oral function which was rarely known. The 
limitations in this study include a young study cohort 
and one dose-response point. On the other hand, the 
strength of the study is the subjects served as their own 
controls before and after treatment, and the study is 
interprofessional including both visual and oral func-
tional tests. The findings from this study serve as a good 
starting point for future studies on the effects of miotics 
on oral and visual functions of patients.  
Generally, the effect of pilocarpine as a miotic can be 
inferred for other drugs that could constrict pupils and 
affect visual function such as opioids and antipsychot-
ics. Unfortunately, there are no alternative choliner-
gic agonists such as pilocarpine that is not a mitotic, 
because cholinergic receptors are abundant in the iris 
sphincter muscle, so knowing its potential visual and 
oral effects would ensure closer monitoring of the side 
effects of the miotics and adjusting the dosage appro-
priately.  
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Conclusions 
This is the first study to investigate the effects of a mi-
otic drug via interprofessional collaborations between 
optometry, pharmacy, and dental health science. The 
authors have better appreciation of other health profes-
sion and establish a good foundation for future collabo-
ration.
In young normal subjects, pilocarpine adversely affects 
the visual acuity, contrast sensitivity, visual field, and 
thus the overall visual function, but it positively in-
creases salivary volume. Future study of the side effects 
of oral pilocarpine is necessary to better understand the 
full impact of oral miotics on visual and oral function.  
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